相关实验视频
Updated: Jul 2, 2025

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
9.0K
临床试验的最新进展 多重系统缩
David Bendetowicz1,2, Margherita Fabbri3,4, Federico Sirna5
1Univ. Bordeaux, CNRS, IMN, UMR5293, Bordeaux, France. david.bendetowicz@u-bordeaux.fr.
Current neurology and neuroscience reports
|February 28, 2024
概括
多重系统缩 (MSA) 的临床试验显示出强大的管道,但成功有限. 未来的神经保护策略需要更好地了解这种罕见的神经退行性疾病的疾病机制和试验设计.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多重系统缩 (MSA) 是一种罕见的,致命的神经退行性疾病.
- 它呈现出帕金森症,小脑和自主功能障碍.
- 目前的研究重点是神经保护策略.
研究的目的:
- 审查MSA中过去和正在进行的神经保护试验.
- 描述MSA的临床前治疗管道.
- 确定MSA中成功临床试验的考虑因素.
主要方法:
- 在MSA中进行神经保护试验的文献综述.
- 临床前治疗管道的分析.
- 讨论临床试验设计要素 (诊断,终点).
主要成果:
- 在MSA临床试验中已经测试了30多种化合物.
- 只有两个化合物满足了它们的主要终点.
- 目前正在进行的试验针对的是MSA的标志性特征alpha-synuclein.
结论:
- 尽管有强大的治疗管道,但试验结果在很大程度上是负面的.
- 更好地了解疾病机制和临床前模型至关重要.
- 改进的临床工具,统计方法和生物标志物将提高未来试验的成功率.
相关概念视频
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188

